|
Note 4 - Segment Information - Financial Information Relating to Reportable Segments (Details) (USD $)
|
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
|
| Net sales: | ||||
| Net Sales | $ 111,948,000us-gaap_SalesRevenueNet | $ 84,017,000us-gaap_SalesRevenueNet | $ 220,425,000us-gaap_SalesRevenueNet | $ 169,685,000us-gaap_SalesRevenueNet |
| Segment operating income | ||||
| Segment Operating Income | 34,580,000us-gaap_OperatingIncomeLoss | 35,744,000us-gaap_OperatingIncomeLoss | 69,796,000us-gaap_OperatingIncomeLoss | 75,135,000us-gaap_OperatingIncomeLoss |
| Cost recognized on sale of acquired inventory | (1,188,000)tech_FairValueWriteUpOfAcquiredInventory | (1,404,000)tech_FairValueWriteUpOfAcquiredInventory | (4,355,000)tech_FairValueWriteUpOfAcquiredInventory | (3,135,000)tech_FairValueWriteUpOfAcquiredInventory |
| Amortization expense | (6,858,000)us-gaap_AmortizationOfIntangibleAssets | (2,587,000)us-gaap_AmortizationOfIntangibleAssets | (12,586,000)us-gaap_AmortizationOfIntangibleAssets | (4,775,000)us-gaap_AmortizationOfIntangibleAssets |
| Corporate selling, general and administrative expenses | (31,137,000)us-gaap_SellingGeneralAndAdministrativeExpense | (14,926,000)us-gaap_SellingGeneralAndAdministrativeExpense | (59,838,000)us-gaap_SellingGeneralAndAdministrativeExpense | (28,947,000)us-gaap_SellingGeneralAndAdministrativeExpense |
| Acquisition related expenses | (1,201,000)us-gaap_BusinessCombinationAcquisitionRelatedCosts | 0us-gaap_BusinessCombinationAcquisitionRelatedCosts | (3,571,000)us-gaap_BusinessCombinationAcquisitionRelatedCosts | (532,000)us-gaap_BusinessCombinationAcquisitionRelatedCosts |
| Corporate, Non-Segment [Member] | ||||
| Segment operating income | ||||
| Corporate selling, general and administrative expenses |
(2,768,000)us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember |
(2,086,000)us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember |
(5,446,000)us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember |
(3,251,000)us-gaap_SellingGeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember |
| Segment Reconciling Items [Member] | ||||
| Segment operating income | ||||
| Segment Operating Income |
46,595,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember |
41,821,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember |
95,754,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember |
86,828,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember |
| Segment Reconciling Items [Member] | Biotechnology [Member] | ||||
| Net sales: | ||||
| Net Sales |
77,951,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
70,557,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
159,419,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
143,747,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
| Segment operating income | ||||
| Segment Operating Income |
39,210,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
38,135,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
81,230,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
79,123,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_BiotechnologyMember |
| Segment Reconciling Items [Member] | Clinical Controls [Member] | ||||
| Net sales: | ||||
| Net Sales |
13,698,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
13,460,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
27,793,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
25,938,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
| Segment operating income | ||||
| Segment Operating Income |
3,818,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
3,686,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
8,353,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
7,705,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ClinicalControlsMember |
| Segment Reconciling Items [Member] | Protein Platforms [Member] | ||||
| Net sales: | ||||
| Net Sales |
20,299,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
0us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
33,213,000us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
0us-gaap_SalesRevenueNet / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
| Segment operating income | ||||
| Segment Operating Income |
$ 3,567,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
$ 0us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
$ 6,171,000us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
$ 0us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember / us-gaap_StatementBusinessSegmentsAxis = tech_ProteinPlatformsMember |
| X | ||||||||||
|
- Definition
The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|